Key Quantitative Figures

Standalone Financial Results (Quarter Ended September 30, 2026):

  • Net Sales/Income from operations: ₹4,579.50 lakh
  • Other Income: ₹1.81 lakh
  • Total Revenue: ₹4,581.31 lakh
  • Total Expenses: ₹4,413.96 lakh
  • Profit before Exceptional Items & Tax: ₹167.35 lakh
  • Total Tax Expenses: ₹39.66 lakh
  • Net Profit for the period: ₹127.69 lakh
  • Earnings Per Share (Basic): ₹0.80
  • Earnings Per Share (Diluted): ₹0.80
  • Paid-up equity share capital: ₹801.62 lakh

Consolidated Financial Results (Quarter Ended September 30, 2026):

  • Income from operations: ₹10,062.89 lakh
  • Other Income: ₹1.35 lakh
  • Total Revenue: ₹10,064.24 lakh
  • Total Expenses: ₹9,384.88 lakh
  • Profit before Exceptional Items & Tax: ₹679.36 lakh
  • Total Tax Expenses: ₹139.80 lakh
  • Net Profit for the period: ₹539.55 lakh
  • Earnings Per Share (Basic): ₹2.30
  • Earnings Per Share (Diluted): ₹2.30
  • Paid-up equity share capital: ₹801.62 lakh

Half Year Comparison (Standalone):

  • Total Revenue (H1 FY27): ₹9,435.83 lakh vs ₹9,307.78 lakh (H1 FY26)
  • Net Profit (H1 FY27): ₹393.21 lakh vs ₹341.15 lakh (H1 FY26)

Half Year Comparison (Consolidated):

  • Total Revenue (H1 FY27): ₹19,794.61 lakh vs ₹18,413.55 lakh (H1 FY26)
  • Net Profit (H1 FY27): ₹989.68 lakh vs ₹712.62 lakh (H1 FY26)

Dates of Action

  • Board meeting held: November 13, 2026
  • Meeting duration: 4:30 PM to 6:00 PM
  • Financial period covered: Quarter and half year ended September 30, 2026
  • Results approved by Board of Directors on November 13, 2026

Parties Involved

  • Auditor: M/s Rahul Chaudhary & Associates, Chartered Accountants (Firm Reg. No. 033971N)
  • Associate Company: Medicamen Biotech Limited (included in consolidated results)
  • Board Chairman: Rahul Bishnoi
  • Company Secretary & Compliance Officer: Parul Choudhary (ACS: 34854)

Business Segments

The company operates in three business segments:

1. Agro Chemicals

2. Active Pharma Ingredient (API)

3. Pharma Formulation

Financial Statements Included

  • Un-Audited Financial Results (Standalone & Consolidated) - Annexure-A
  • Unaudited Segment-wise Revenue, Results, Assets and Liabilities - Annexure-B
  • Limited Review Report from auditors - Annexure-C

Assets and Liabilities (Standalone as of September 30, 2026)

  • Total Assets: ₹54,215.15 lakh
  • Total Equity: ₹42,076.55 lakh
  • Non-current liabilities: ₹2,400.27 lakh
  • Current liabilities: ₹9,738.33 lakh
  • Property Plant & Equipment: ₹25,078.28 lakh
  • Investments: ₹8,109.13 lakh

Cash Flow Statement (Standalone H1 FY27)

  • Net Cash Flow from Operating Activities: ₹1,254.70 lakh
  • Net Cash Flow from Investing Activities: ₹(611.55) lakh
  • Net Cash Flow from Financing Activities: ₹992.77 lakh
  • Net increase in Cash & Cash Equivalents: ₹1,635.91 lakh
  • Cash & Cash Equivalents at period end: ₹1,946.27 lakh

Audit Review

Limited review conducted by M/s Rahul Chaudhary & Associates in accordance with Standard on Review Engagements (SRE) 2410. The review report states that nothing has come to their attention that causes them to believe the financial results contain any material misstatement.

Additional Information

  • Corporate Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
  • Results available on company website: www.shivalikrasayan.com
  • Figures regrouped in previous year where considered necessary